The latest study conducted in the center, housed in the College of Agricultural Sciences, investigated how eating behavior changes when consumers are served a dip with a salty snack. The findings, available online now and to be published in the November issue of Food Quality and Preference, suggest that they eat more — a lot more. The chips and dip together yielded a 77% greater caloric intake, and a faster total eating rate compared to the just chips, no-dip control.

However, there was no difference in chip intake, pointed out study corresponding author John Hayes, professor of food science and director of the Penn State Sensory Evaluation Center.

“The most striking findings of our study is that people didn’t eat fewer chips when dip was available — they ate the same amount of chips, plus the dip,” he said. “This lack of compensation means that adding dip to chips can substantially increase overall energy intake without people realizing it.”

Intuitively, many people would guess that if we add something extra to a snack, like dip, people will compensate, and eat less of the main item, Hayes explained.

“But our research shows this is not the case with chips and dip,” he said. “Our participants consumed the same amount of chips regardless of whether dip was present, leading to much greater energy intake when dip was available.”

The study, which was led by research assistant Madeline Harper, who recently graduated from Penn State with a master’s degree in food science, assessed 46 adult participants. In two visits to the Sensory Evaluation Center, they were served 70 grams of ranch-flavored chips, or about 2.5 servings, with or without about a third of a cup of ranch dip. Participants ate as much as they wanted.

Their intake was measured, and all eating sessions were video recorded and annotated for number of bites and active eating time. Researchers used that information to calculate measures of “eating microstructure,” including eating rate and bite size.

Harper suggested that the greater intake of the chips and dip snack was facilitated by a larger bite size resulting from dip inclusion. On average per eating session, participants consumed 345 calories of chips and dip compared to 195 calories of chips alone.

The study was novel, Harper noted, because little research has been conducted on the effect of external sources of oral lubrication like dips on oral processing of salty snacks.

“Clearly, it has an influence on food intake, especially while snacking,” she said. “However, in this chips-and-dip snack, the greater intake resulting from dip inclusion may have been facilitated by a larger total snack bite size, as opposed to faster chip eating rate.”

Even though snacking is a major source of energy in the typical American diet, it remains understudied, Hayes said, adding that understanding eating behavior around snacking is crucial to address issues of overeating and obesity.

“This research opens up new avenues for exploring how the physical properties of foods can influence our eating behaviors and ultimately, our energy intake,” he said. “If we can slow people down, we can influence energy consumption without giving up the pleasure from food.”

Paige Cunningham, postdoctoral scholar in the Department of Food Science and the Department of Nutritional Sciences at Penn State, contributed to the research.

The U.S. Department of Agriculture’s National Institute of Food and Agriculture supported this research.

Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the four subtypes a patient has, but the worst survival rates, historically at about 40%, are for Group 3, which this research focused on.

Jezabel Rodriguez Blanco, Ph.D., an assistant professor who holds dual appointments at MUSC Hollings Cancer Center and the Darby Children’s Research Institute at MUSC, led the research, published in the Journal of Clinical Investigation.

Her research focused on the drug triptolide, which is extracted from a vine used in traditional Chinese medicine, and its water-soluble prodrug version, Minnelide. A prodrug is an inactive medication that the body converts into an active drug through enzymatic or chemical reactions.

MYC is an oncogene, or gene that has the potential to cause cancer. MYC is dysregulated, or out of control, in about 70% of human cancers, and it shows up in much higher levels in Group 3 medulloblastoma than in the other medulloblastoma subgroups. Despite its well-known role in cancer, this oncogene historically has been considered impossible to target with drugs.

Despite its poor druggability, previous research in other cancers had shown that triptolide and its derivatives had the ability to target MYC. When Blanco was still a postdoctoral fellow at the University of Miami, her mentor, David Robbins, Ph.D., attended a presentation by the research team that showed that the more copies of MYC that a tumor has, the better that triptolide works.

“He came to me, and he told me, ‘You know, as Group 3 medulloblastoma has many MYC copies, you should get some research models and try the drug,” Blanco recalled. She started the project from scratch. “I started talking to people, getting cell lines and animal models, learning how to propagate them, getting the drug, using it.”

Blanco received a three-month grant intended for cancer center trainees to develop ideas. Then her lab at the time was awarded a one-year grant from the Southeastern Brain Tumor Foundation in 2018. Since then, she’s received no additional funding specific to this project. Even as she started her faculty position at MUSC and began to focus most of her research on the Sonic Hedgehog subgroup of medulloblastoma, she continued to work on the Group 3 research as a side project. She knew how well triptolide was working in these hard-to-treat tumors, and she did not want her initial results to fall through the cracks.

Determining the mechanism of action has been the most challenging part of the project, she noted, due to the drug’s multiple effects, and there could still be additional mechanisms beyond those that Blanco identified.

“It was affecting MYC gene expression by affecting the RNA pol II activity, and then it was affecting how long the protein lasts. So, the fact that it’s working through two different mechanisms on this oncogene may explain why it’s so effective in tumors that have extra copies of MYC,” she said, explaining that RNA polymerase II is a protein that helps to make copies of DNA instructions, which are used to produce proteins in the cell.

Despite the challenges of narrowing down the mechanism of action specific to the cancer, it was quite clear that however it worked, it did work, she said.

The efficacy was 100 times higher in the Group 3 tumors with extra MYC copies than in the Sonic Hedgehog tumors with normal levels of MYC, she said. She found that Minnelide reduced tumor growth and the spread of cancer cells to the thin tissues that cover the brain and spinal cord, called leptomeninges. It also increased the efficacy of the chemotherapy drug cyclophosphamide, which is currently used in treatment.

Blanco decided to move forward with publication rather than waiting to write a manuscript that answered all possible questions. Knowing that most parents whose children receive a Group 3 medulloblastoma diagnosis will lose their child in less than two years was the incentive she needed to push this work out.

“There was a point at which I could not hold these data anymore because it was working so well that it needed to go out,” she said. “The preclinical models were showing such a nice efficacy that it was like, ‘OK, I cannot keep on holding this work, digging deeper into the mechanism of action because the kids that have Group 3 medulloblastoma are dying while we are doing those experiments.”

Minnelide has been tested or is currently in testing in phase I and phase II clinical trials of adults with different types of cancer, including pancreatic cancer, where it showed some efficacy.

Blanco is hopeful that, with this new research on Group 3 medulloblastoma, a clinical trial for children with this disease can be launched.

That would make the tropical Andes the first region in the world known to pass that threshold as a result of the steadily warming global climate. It also makes them possible harbingers of what’s to come for glaciers globally.

“We think these are the canary in the coal mine. The tropics would probably be the first place you’d expect ice to disappear, and that’s what we’re seeing,” says Shaun Marcott, a professor of geoscience at UW-Madison. Marcott guided the research with colleagues at Boston College and Tulane University. Andrew Gorin, a former Boston College graduate student who is now at University of California, Berkeley, led the study, which appears in the Aug. 2, 2024, issue of the journal Science.

Glaciers grow slowly over time in regions where summer weather isn’t warm enough to melt all of the previous winter’s snowfall. Over time, unmelted snow collects and gets compacted and begins to move under its own weight, resulting in the year-round ice that defines a glacier.

Satellite imagery and on-the-ground observations have provided conclusive evidence for decades that high-altitude glaciers in the Andes are steadily shrinking as warmer temperatures cause them to melt more quickly than falling snow can replenish them.

What has remained unclear, though, is whether the glaciers’ dwindling footprints are anomalously small compared to the rest of the period that began at the end of the last ice age, known as the Holocene. Meanwhile, glaciers in other parts of the world were smaller at some points in the early Holocene, when the global climate was warmer and drier than recent millennia.

“We knew that glaciers ebbed and flowed in the past, so we wanted to learn how the behavior of glaciers today — melting due to human-caused climate change — stacks up against their long-term fluctuations,” says Andy Jones, a UW-Madison doctoral student and study co-author.

To answer this question, the team of scientists analyzed the geochemistry of bedrock from areas near the edges of four glaciers in the high tropical Andes, choosing sites that satellite imagery showed were exposed by melting ice in only the last two or three decades.

The team specifically looked for evidence of two unique isotopes — basically chemical flavors — of a pair of elements with the bedrock’s quartz crystals: beryllium-10 and carbon-14. These isotopes are only present in rock that has spent time at or near the Earth’s surface as they result from interactions between the rock and cosmic rays, which are high-energy particles that constantly rain down on the planet from outer space.

Bedrock accumulates beryllium-10 and carbon-14 once it’s exposed to the surface, so measuring the isotopes’ concentrations in rock crystals near glaciers can be useful for understanding the previous extent of ice coverage. The team found “remarkably low” concentrations of both isotopes in nearly all samples, suggesting that melting ice has exposed bedrock near the glaciers for the first time only recently in most of the sampled locations.

Additional analyses — and the fact that the extremely low concentrations were consistent across sample sites — made the researchers confident that melting ice, rather than erosion, exposed the bedrock.

“It’s highly unlikely this is from erosion,” says Marcott. “Because the multiple locations we went to all show the same thing.”

This consistency points to a single likely conclusion, according to Marcott: The world’s tropical glaciers, more than 99% of which are located in the Andes, are the first to shrink beyond what’s been seen in the recent geologic past.

“Glaciers are very sensitive to the climate system that they live in,” says Marcott. “They really are the place you would look to see some of the first big changes resulting from a warming climate. You can look to these glaciers and imagine what we might be looking at going into the future in other places like the Western United States, which is a no-ice scenario.”

This research was supported by the National Science Foundation (EAR-1805620; EAR-1805133; EAR-1805892).